EGFR and neoplasm: Notably, among the patients harboring an EGFR 19DEL or L858R mutation, 15 received EGFR‐TKI therapy as first‐line treatment and had a tumor response assessment (10 partial responses [PR], three stable diseases [SD], and two progressive diseases [PD]) with 11 patients achieving PFS, while seven received chemotherapy and had a tumor response assessment (two PR, three SD, and two PD) with six patients achieving PFS.